<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2796">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320277</url>
  </required_header>
  <id_info>
    <org_study_id>HPrato-3</org_study_id>
    <nct_id>NCT04320277</nct_id>
  </id_info>
  <brief_title>Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.</brief_title>
  <acronym>BARI-COVID</acronym>
  <official_title>Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital of Prato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital of Prato</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no specific antiviral treatment recommended for COVID-19, and no vaccine is
      currently available. Baricitinib, an anti-Janus kinase inhibitor (anti-JAK) acting against
      JAK1 and JAK2. The drug was found capable to reduce or interrupt the passage of the virus
      into target cells, and to inhibit the JAK1- and JAK2-mediated cytokine release. The drug was
      licensed for the treatment of rheumatoid arthritis at the daily dose of 4 mg/orally, with
      excellent results in terms of clinical response and a good safety profile. Since baricitinib
      does not interact with antivirals due to its prevalent renal elimination, it may be used in
      combination.The evidence on the advantageous action of baricitinib on viral entry and
      cytokine outbreak constituted the rationale to perform a trial on patients with mild to
      moderate COVID-19 infection receiving baricitinib combined with antiviral therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design. Interventional, open-label, 2-week, prospective trial of a cohort of patients
      with mild to moderate COVID-19 infection.

      Objectives. Primary. To assess the efficacy of baricitinib combined with antiviral therapy in
      patients with COVID-19-related mild and moderate disease in terms of reduction of the
      percentage of subjects requiring ICU admission.

      Secondary objectives. To describe the clinical findings in a cohort of symptomatic
      COVID-19-infected subjects; to investigate the role of CRP, IL-6, and TNFα levels as
      predictor of progression to ARDS; to assess the type and incidence of adverse events (AEs).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 16, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients. All consecutive patients with mild to moderate COVID-19 infection, older than 18, Patients should present fever, cough and myalgia and weakness and radiological findings of pneumonia.
Controls. All consecutive patients with mild to moderate COVID-19 infection, older than 18, admitted during the previous 2 weeks, who were treated with antiviral and/or hydroxychloroquine.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The percentage of ICU admission in patients and controls will be compared for statistical difference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients achieving the remission; CRP, IL-6 and TNFα values at baseline and during the treatment course; the number of AEs.</measure>
    <time_frame>2 weeks</time_frame>
    <description>CRP values will be evaluated for prediction of disease worsening.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pharmacological Action</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients received baricitinib combined to antiviral therapy lopinavir/ritonavir for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All consecutive patients with mild to moderate COVID-19 infection, older than 18, a during the previous 2 weeks, who were treated with antiviral and/or hydroxychloroquine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
    <other_name>Lopinavir/Ritonavir tablets 250 mg/bid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All consecutive patients with mild to moderate COVID-19 infection

          -  Age &gt;18 years,

          -  Clinical diagnosis of COVID19 infection

          -  Patients should present fever, cough and myalgia and weakness and radiological
             findings of pneumonia.

          -  All patients should be willing and able to provide written informed consent prior to
             performing study procedures.

        Exclusion Criteria:

          -  Age less than 18

          -  History of thrombophlebitis.

          -  Patient with latent tuberculosis infection (Quantiferon test).

          -  Pregnancy and lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrizio Cantini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital of Prato, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrizio Cantini, MD</last_name>
    <phone>+393408075607</phone>
    <email>fbrzcantini@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Niccoli, MD</last_name>
    <phone>+39 3339849690</phone>
    <email>lniccoli64@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fabrizio Cantini</name>
      <address>
        <city>Prato</city>
        <state>Tuscany</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabrizio Cantini</last_name>
      <phone>+39 3408075607</phone>
      <email>fbrzcantini@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x. Epub 2017 May 2. Review.</citation>
    <PMID>28466096</PMID>
  </reference>
  <reference>
    <citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.</citation>
    <PMID>31978945</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.</citation>
    <PMID>32187464</PMID>
  </reference>
  <reference>
    <citation>Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, Savory E, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4. Erratum in: Lancet. 2020 Jun 20;395(10241):1906.</citation>
    <PMID>32032529</PMID>
  </reference>
  <reference>
    <citation>Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019 Oct 1;58(10):1755-1766. doi: 10.1093/rheumatology/kez087.</citation>
    <PMID>30982883</PMID>
  </reference>
  <reference>
    <citation>Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.</citation>
    <PMID>32113509</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>April 19, 2020</last_update_submitted>
  <last_update_submitted_qc>April 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital of Prato</investigator_affiliation>
    <investigator_full_name>Fabrizio Cantini</investigator_full_name>
    <investigator_title>Head of Rheumatology Department, Principal investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Baricitinib</keyword>
  <keyword>Moderate disease</keyword>
  <keyword>Infection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

